Overview

Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

Status:
NOT_YET_RECRUITING

Trial end date:
2032-12-31

Target enrollment:

Participant gender:

Summary

This is phase III randomized, multicenter study adding or not intra-venous Liposomal Trasncrocetin (L-TC) to hypofractionated radiotherapy and concomitant Temozolomide followed by adjuvant Temozolomide in patients with histologically confirmed diagnosis of glioblastoma (GBM).

Phase:

PHASE3

Details

Lead Sponsor:

Institut de cancérologie Strasbourg Europe

Collaborator:

LEAF4Life, Inc.

Treatments:

Radiotherapy
Temozolomide